A comprehensive review of neurological disorders reported during the current coronavirus disease 2019 (COVID-19) pandemic demonstrates that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the central nervous system (CNS), the peripheral nervous system (PNS) and muscles, leading the Environmental Neurology Specialty Group of the World Federation of Neurology to propose implementation of international neurological registries.
Researchers from the Hong Kong Baptist University (HKBU) have developed an extracellular inorganic nanomatrix that induces rapid and specific differentiation of neural stem cells (NSCs) into miniature substantia nigra-like structures (mini-SMLSs) without the use of growth factors (GFs). Transplantation of differentiated neurons from these mini‐SNLSs has shown an early and progressive amelioration of Parkinson’s disease (PD) in rats.
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients with nonMuSK+* generalized myasthenia gravis (gMG), early initiation of therapy with the B-cell–depleting monoclonal antibody rituximab may improve treatment outcomes compared with conventional immunosuppressant therapy**, a Swedish retrospective analysis has shown.
There is not enough evidence to support the claim that multiple sclerosis (MS) disease-modifying therapies (DMTs) increase the risk of infection with SARS-CoV-2, the virus that causes the novel coronavirus disease (COVID-19), suggests a recent review article.
New drug applications approved by US FDA as of 01 - 15 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A Chinese cross-sectional case-control study has identified time spent following news on coronavirus disease 2019 (COVID-19) and drug-resistant epilepsy as two independent predictors of severe psychological distress among epilepsy patients during the COVID-19 pandemic.
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Acne is a common skin problem seen in primary care. Dr Wong
Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore
shares his insights with Pearl Toh on how to manage acne in the primary care
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.